Latest Field Trials Validate Strength of Biotalys’ First Biocontrol Evoca
Ghent, Belgium, May 19, 2022 (GLOBE NEWSWIRE) --
- With more than 600 trials now complete, 150 of which took place in 2021, the Biotalys global field trial program continues to prove the strength and efficacy of its first biofungicide Evoca
- Evoca outperformed a leading chemical productwhen applied at the flowering stage of grapes in a fungicide rotation program
- Following EPA regulatory approval expected later this year, Evoca willbecome available toU.S. growers looking for new tools to protect their crops more sustainably
Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, today unveiled the promising results of its latest field trials with its biocontrol Evoca™*. In 2021, an extensive program of 150 trials was conducted to further support the regulatory dossier for Evoca in the EU, and to refine commercial positioning of the product in the US. The trials showed that, when applied at the flowering stage in a Botrytis control program in grape, Evoca consistently outperformed a leading chemical fungicide. This demonstrates Evoca’s potential as a pivotal tool to fight Botrytis, a costly and often devastating fungal disease.
“Our field trial program continues to demonstrate the intrinsic strength of our first protein-based biocontrol Evoca. The latest results provide clear information on the product’s ideal positioning, highlighting a distinct commercial opportunity for Biotalys to position Evoca within a grower’s integrated pest management rotation,” said Patrice Sellès, CEO of Biotalys. “Adding more biocontrol solutions, like Evoca, into the hands of growers is essential for the transition to safer, more sustainable agricultural practices. Studying in-field results helps us develop best practices for how and when to add biocontrols into the traditional protection mix so growers can confidently use the right program and the right inputs at the right time based on the unique needs of their crops.”
Based on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Evoca provided excellent preventative control of Botrytis bunch rot in grapevines. The efficacy trials assessed applications for wine/table grapes at flowering, bunch closure, and veraison (respectively applications A, B, and C in the image below). When substituted for a leading chemical fungicide at the flowering stage in a commercial “gold standard” chemical fungicide rotation, Evoca provided significantly more control of Botrytis in grapes at harvest. Indeed, the Evoca program suppressed severity of bunch rot symptoms by approximately 73% when compared to untreated bunches, versus only 54% for the rotation program with only chemical fungicides.
“As resistance to conventional crop protection solutions continues to build, growers are looking for new, effective yet sustainable ways to protect their yields, their soil health, their livelihoods and their ecosystem,” said Carlos Reyes, Head of Field Development at Biotalys, based in California. “Adding Evoca to an IPM program at flowering – the optimum growth stage for a clean start of the cultivation – will not only provide a competitive advantage for grape growers, but will also give them the added confidence that they are giving their crop a strong start with season-long impact, as well as eliminating initial chemical fungicide applications.”
Building on these findings, Biotalys has already progressed with additional trials to also explore at-flowering sprays within IPM programs in berries, cucurbits and tomatoes as the company continues to deepen its field trial data from around the globe.
In addition, Biotalys has demonstrated that wine grape juice quality, vinification or wine characteristics exhibited no differences for Evoca-treated vineyards when compared to non-Evoca treated vineyards. Samples from Chardonnay, Pinot Gris, Pinot Noir, and Merlot vineyards treated with Evoca at various stages of the grape lifecycle were subjected to nearly 50 different analytical laboratory analyses in accordance with industry standards. These results were jointly reviewed and validated by the Manager of Technical, Environmental, and International Affairs and the Analytical Lab Manager of a major California wine producer, thus demonstrating Biotalys’ ability to offer the wine industry an innovative new solution that protects vineyards while ensuring the quality of the fresh produce and derivatives.
A novel protein-based biofungicide developed on Biotalys’ AGROBODY Foundry™ platform, Evoca helps control fungal diseases such as Botrytis in fruits and vegetables. Demonstrating strong performance across more than 600 independent and company-driven field and greenhouse trials across multiple regions, climates, soil types, production types, pathogen pressure and crops to date, Evoca is on track to obtain approval by the U.S. Environmental Protection Agency (EPA) later this year, while in the EU regulatory approval is expected by the end of 2024. This will pave the way for Biotalys’ pipeline of product candidates, which includes biofungicides, biobactericides and bio-insecticides.
Earlier in May 2022, Evoca’s active ingredient received an entirely new resistance class by the FRAC – the Fungicide Resistance Action Committee. The new classification granted by this highly-reputed international panel of renown technical experts, demonstrates to growers that the product will be a new tool that complements existing biological and conventional crop protection solutions to fight the fungal diseases Botrytis and powdery mildew.
* Evoca™: Pending Registration. This product is not currently registered for sale or use in the United States, the European Union,or elsewhere and is not being offered for sale.
Biotalys is an Agricultural Technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
For further information, please contact
Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.
- Picture1 in press release
- Picture2 in press release
- Biotalys Press Release - Latest Field Trials Validate Strength of Biotalys' First Biocontrol Evoca
- Biotalys Persbericht - Meest recente veldproeven bevestigen kracht van Evoca
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Millicom increases Tigo Panama ownership to 100%29.6.2022 23:36:16 CEST | Press release
Millicom increases Tigo Panamaownership to 100% Luxembourg, June 29, 2022 – Millicom closed today the previously-announced transaction to acquire the remaining 20% interest in Telecomunicaciones Digitales, S.A. (formerly known as Cable Onda S.A. or “Tigo Panama”) reflecting an exercise of the founders’ liquidity option as provided for in the Shareholders’ Agreement, which was entered into in 2018. As a result, Millicom now owns 100% of Tigo Panama, the leader in Panama’s telecommunications market. For further information, please contact: Press: Yocasta Valdez, Sr. Manager Digital Media & Communications email@example.com Investors: Michel Morin, VP Investor Relations Sarah Inmon, Director Investor Relations firstname.lastname@example.org About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile telecommunications services in Latin America. Through our TIGO® and Tigo Business® brands, we provide a wide range of digital services and product
Kalera Public Limited Company announces its share structure following the business combination with Agrico Acquisition Corp.29.6.2022 16:30:19 CEST | Press release
ORLANDO, Fla., June 29, 2022 (GLOBE NEWSWIRE) -- Kalera Public Limited Company ( “Kalera”) and Agrico Acquisition Corp. (“Agrico”) today announced the completion of their previously announced business combination. The combined company will retain the Kalera name and will commence trading ordinary shares (“Kalera Shares”) and warrants (“Kalera Warrants”) on Nasdaq under the new ticker symbols “KAL” and “KALWW”, respectively, on Wednesday, June 29, 2022. The business combination was approved at a special meeting of the shareholders of Kalera S.A. on June 28, 2022. Update on Share Structure Pursuant to the Sponsor Support Agreement entered into on January 30, 2022, upon the consummation of the business combination approximately 1.8 million shares (50%) of Agrico Class B common stock were first converted into Agrico Class A common stock on a one-for-one basis, then into Kalera Shares on a one-for-one basis. The remaining 50% of the Agrico Class B common stock was forfeited to Agrico. In co
Business School Graduates Enter White-Hot Job Market as Employers Signal Growth, Confidence in Their Credentials29.6.2022 16:00:00 CEST | Press release
MBA and business master’s degrees remain hot commodity despite recession fears and COVID challenges RESTON, Va., June 29, 2022 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today released its annual hiring report, the GMAC Corporate Recruiters Survey – 2022 Summary Report. The report explores the state of employer demand for graduate business school talent (MBA and business master’s degree recipients) in the context of the COVID-19 pandemic and includes responses from nearly 1,000 corporate recruiters and staffing firms around the world. While rising inflation and the war in Ukraine were just at the onset during the time when the survey was conducted in February and March 2022, hiring projections of graduate management education (GME) graduates remain bullish this year, with 92 percent of corporate recruiters expecting to hire newly minted MBAs. Promisingly, 2 in 3 responding corporate recruiters describ
AGC Biologics Named Manufacturing Company of the year by American Business Awards29.6.2022 15:09:00 CEST | Press release
Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites SEATTLE, June 29, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it was named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®. The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. More than 230 professionals worldwide participated in the judging process to select this year’s American Business Award winners. AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents. Over the last two years, the company has expanded its capabilities and reach with
PGS ASA: Approval and publication of prospectus – Listing of shares and Subsequent Offering29.6.2022 15:01:52 CEST | Press release
29 June, 2022 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the previous stock exchange announcements by PGS ASA (“PGS” or the “Company”) regarding a successfully placed private placement (the "Private Placement") of new shares in the Company, raising gross proceeds of approximately NOK 800 million and a potential subsequent offering (the “Subsequent Offering) of up to 38,155,803 new shares at a subscription price of NOK 3.70, and the Company’s extraordinary general meeting’s approval of the same on 27 May 2022. The Private Placement consisted of one tranche of 74,200,000 new shares ("Tranche 1") and a second tranche of 142,016,216 new shares ("Tranche2"). T